Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]

Intellipharmaceutics advances abuse-deterrent oxycodone

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has taken delivery of and fully qualified its primary manufacturing equipment for the manufacture of oxycodone CR, an abuse-deterrent formulation of controlled-release oxycodone hydrochloride. The company also said it has begun making clinical batches of the drug for Phase 1 studies and to establish a clinical program in cooperation with the [...]